Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Determinants of disability using count-based approaches to icf-based definition of neurological disability.
A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Trials Examining the Clinical Efficacy of Vitamin D in Multiple Sclerosis.
Magnetic susceptibility anisotropy: Cylindrical symmetry from macroscopically ordered anisotropic molecules and accuracy of MRI measurements using few orientations.
Neuroinflammation as the proximate cause of signature pathogenic pattern progression in amyotrophic lateral sclerosis, AIDS, and multiple sclerosis.
Facilitation of Corticospinal Connections in Able-bodied People and People With Central Nervous System Disorders Using Eight Interventions.
Expression Analysis of CB2-GFP BAC Transgenic Mice.
Murine experimental autoimmune encephalomyelitis is diminished by treatment with the angiogenesis inhibitors b20-4.1.1 and angiostatin (k1-3).
Erratum to: Genomic Binding Sites and Biological Effects of the Vitamin D-VDR Complex in Multiple Sclerosis.
A Group Kickboxing Program for Improving Balance, Mobility, and Quality of Life in Individuals With Multiple Sclerosis: A Pilot Study.
Anti-aquaporin-4 IgG in Patients Presenting with Unilateral Optic Neuritis: A Cohort Study.
Cognitive impairment among different clinical courses of multiple sclerosis.
Oropharyngeal dysphagia in patients with multiple sclerosis: do the disease classification scales reflect dysphagia severity?
Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis.
Effects of Physical Exercise on Neuroinflammation, Neuroplasticity, Neurodegeneration, and Behavior: What We Can Learn From Animal Models in Clinical Settings.
Weekly multimodal MRI follow-up of two multiple sclerosis active lesions presenting a transient decrease in ADC.
Abnormally high levels of anti-collagen type IV IgG antibodies in the serum of patients with a clinically isolated syndrome correlate with an increased risk of conversion to MS.
High-mobility group box 1 in multiple sclerosis.
Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients.
Deleterious versus protective autoimmunity in multiple sclerosis.
Cerebrospinal Fluid High-Mobility Group Box Protein 1 in Neuromyelitis Optica and Multiple Sclerosis.
Protective Role of (RS )-glucoraphanin Bioactivated with Myrosinase in an Experimental Model of Multiple Sclerosis.
Early and Degressive Putamen Atrophy in Multiple Sclerosis.
Efficacy and safety of FTY720 in patients with relapsing multiple sclerosis
Something Old, New, Borrowed, Blue: Anthracenedione Agents for Treatment of Multiple Sclerosis.
The fatigue-motor performance paradox in multiple sclerosis.

Pages